Trial Profile
A Multicenter, Phase II Clinical Study of Adjuvant Apatinib After IMRT With Concurrent Chemotherapy Versus IMRT With Concurrent Chemotherapy in High-risk Metastasis of Nasopharyngeal Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Cisplatin
- Indications Cancer metastases; Nasopharyngeal cancer
- Focus Therapeutic Use
- 08 Aug 2018 New trial record